Paper Details

  1. Home
  2. Paper Details

Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.

Author: FuchsH J, HuseD M, LaceyM J, OsterG, ReganM M

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

rhDNase therapy reduced the costs of treating RTIs in patients with cystic fibrosis; assuming once-daily dosing, these savings would offset about one-third of the cost of such therapy.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To assess the effects of recombinant human DNase (rhDNase) therapy on the cost of treating respiratory tract infections (RTIs) in patients with cystic fibrosis. DESIGN: We prospectively documented the use of healthcare services among 968 patients with cystic fibrosis who participated in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/106002809502900501

データ提供：米国国立医学図書館（NLM）

Recombinant Human DNase: A Breath of Fresh Air for Cystic Fibrosis Patients

Cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs, is a challenging condition with a significant impact on quality of life. This study explores the use of recombinant human DNase (rhDNase), a medication that helps clear mucus from the lungs, in managing CF. The researchers investigated the impact of rhDNase on healthcare utilization and costs, providing insights into the economic implications of this important treatment.

Unveiling the Economic Impact of rhDNase: A Cost-Effective Approach

This research, like a caravan seeking the most efficient route through the desert, examines the cost-effectiveness of rhDNase in managing CF. The study found that rhDNase therapy significantly reduced the costs associated with treating respiratory tract infections (RTIs), a common complication of CF. This finding, like discovering a well-stocked oasis in the desert, underscores the potential for rhDNase to improve both clinical outcomes and economic efficiency in CF management.

Managing CF: A Path to Improved Quality of Life

Living with CF can be a demanding journey, like navigating a vast and unforgiving desert. However, this study offers hope, highlighting the potential for rhDNase to improve quality of life for CF patients. By reducing the frequency and severity of RTIs, rhDNase can alleviate symptoms, improve lung function, and ultimately enhance overall well-being. While CF remains a complex and challenging condition, this study offers a glimmer of hope, suggesting a path toward a brighter future for CF patients.

Dr.Camel's Conclusion

This study, like a beacon illuminating a path through the desert, provides valuable insights into the cost-effective management of CF. The findings underscore the potential for rhDNase to improve both clinical outcomes and economic efficiency. As we continue to explore the vast landscape of CF research, we must strive to develop innovative and affordable treatments that empower patients to navigate this challenging condition with greater ease and resilience.

Date :
  1. Date Completed 1995-09-29
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

7655127

DOI: Digital Object Identifier

10.1177/106002809502900501

Related Literature

Article Analysis
・Effects of dnase
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.